Seminars in Pediatric Neurology
Volume 15, Issue 2 , Pages 79-90 , June 2008

Pediatric Sleep Pharmacology

  • Rafael Pelayo, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Rafael Pelayo, MD, Stanford Sleep Disorders Clinic, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, Tel 650-723-6601, Fax 650-725-8910
    • ,
  • Michael Dubik, MD

References 

  1. Schnoes CJ, Kuhn BR, Workman EF, et al. Pediatric prescribing practices for clonidine and other pharmacologic agents for children with sleep disturbance. Clin Pediatr (Phila). 2006;45:229–238
  2. Owens JA, Rosen CL, Mindell JA. Medication use in the treatment of pediatric insomnia: Results of a survey of community-based pediatricians. Pediatrics. 2003;111:e628–e635
  3. Stojanovski SD, Rasu RS, Balkrishnan R, et al. Trends in medication prescribing for pediatric sleep difficulties in US outpatient settings. Sleep. 2007;30:1013–1017
  4. Pelayo R, Chen W, Monzon S, et al. Pediatric sleep pharmacology: You want to give my kid sleeping pills?. Pediatr Clin North Am. 2004;51:117–134
  5. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025–1030
  6. International Classification of Sleep Disorders. (ed 2). Westchester, IL: American Academy of Sleep Medicine; 2005;
  7. Morgenthaler TI, Owens J, Alessi C, et al. Practice parameters for behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep. 2006;29:1277–1281
  8. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: An update (An American Academy of Sleep Medicine report). Sleep. 2006;29:1415–1419
  9. Wyatt JK. Delayed sleep phase syndrome: Pathophysiology and treatment options. Sleep. 2004;27:1195–1203
  10. Chesson AL, Littner M, Davila D, et al. Practice parameters for the use of light therapy in the treatment of sleep disorders (Standards of Practice Committee, American Academy of Sleep Medicine). Sleep. 1999;22:641–660
  11. Johnson MW, Suess PE, Griffiths RR. Ramelteon: A novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006;63:1149–1157
  12. Stigler KA, Posey DJ, McDougle CJ. Ramelteon for insomnia in two youths with autistic disorder. J Child Adolesc Psychopharmacol. 2006;16:631–636
  13. Goodman and Gilman's the Pharmacologic Basis of Therapeutics. (ed 9). New York, NY: Macmillan Publishing Co; 1996;
  14. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000;105:S622–S627
  15. Duke C, Rimsza M. Case 1 presentation of bizarre behaviors. Pediatr Rev. 1998;19:245–246
  16. Russo RM, Gururaj VJ, Allen JE. The effectiveness of diphenhydramine HCI in pediatric sleep disorders. J Clin Pharmacol. 1976;16:284–288
  17. Baker AM, Johnson DG, Levisky JA, et al. Fatal diphenhydramine intoxication in infants. J Forensic Sci. 2003;48:425–428
  18. Labeling of diphenhydramine-containing drug products for over-the-counter human use (Final rule). Fed Regist. 2002;67:72555–72559
  19. Bender BG, McCormick DR, Milgrom H. Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine. J Pediatr. 2001;138:656–660
  20. Yanai K, Ryu JH, Watanabe T, et al. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol. 1995;116:1649–1655
  21. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: Functional neuroimaging of histamine H1 receptors in human brain. Life Sci. 2002;72:409–414
  22. Gengo F, Gabos C, Miller JK. The pharmacodynamics of diphenhydramine-induced drowsiness and changes in mental performance. Clin Pharmacol Ther. 1989;45:15–21
  23. Albert KS, Hallmark MR, Sakmar E, et al. Pharmacokinetics of diphenhydramine in man. J Pharmacokinet Biopharm. 1975;3:159–170
  24. Merenstein D, Diener-West M, Halbower AC, et al. The trial of infant response to diphenhydramine: The TIRED study—A randomized, controlled, patient-oriented trial. Arch Pediatr Adolesc Med. 2006;160:707–712
  25. Dinndorf PA, McCabe MA, Frierdich S. Risk of abuse of diphenhydramine in children and adolescents with chronic illnesses. J Pediatr. 1998;133:293–295
  26. Nigro N, Eandi M. Sleep: Notes on pediatric pharmacotherapy (in the light of current knowledge of its principal characteristics). Minerva Pediatr. 1975;27:1999–2007
  27. Pershad J, Palmisano P, Nichols M. Chloral hydrate: The good and the bad. Pediatr Emerg Care. 1999;15:432–435
  28. Loewy J, Hallan C, Friedman E, et al. Sleep/sedation in children undergoing EEG testing: a comparison of chloral hydrate and music therapy. Am J Electroneurodiagnostic Technol. 2006;46:343–355
  29. Haydon RC. Are second-generation antihistamines appropriate for most children and adults?. Arch Otolaryngol Head Neck Surg. 2001;127:1510–1513
  30. Meltzer EO. Comparative safety of H1 antihistamines. Ann Allergy. 1991;67:625
  31. Corey JP, Houser SM, Ng BA. Nasal congestion: A review of its etiology, evaluation, and treatment. Ear Nose Throat J. 2000;79:690–693696, 698 passim
  32. Touitou Y. Human aging and melatonin (Clinical relevance). Exp Gerontol. 2001;36:1083–1100
  33. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998;32:680–691
  34. Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BMJ. 2006;332:385–393
  35. Jan JE, Tai J, Hahn G, Rothstein RR. Melatonin replacement therapy in a child with a pineal tumor. J Child Neurol. 2001;16:139–140
  36. Smits MG, Nagtegaal EE, van der Heijden J, et al. Melatonin for chronic sleep onset insomnia in children: A randomized placebo-controlled trial. J Child Neurol. 2001;16:86–92
  37. Weiss MD, Wasdell MB, Bomben MM, et al. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry. 2006;45:512–519
  38. Van der Heijden KB, Smits MG, Van Someren EJ, et al. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46:233–241
  39. Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders—A case series. Eur Child Adolesc Psychiatry. 2005;14:34–40
  40. Ashton H. Guidelines for the rational use of benzodiazepines (When and what to use). Drugs. 1994;48:25–40
  41. Wills L, Garcia J. Parasomnias: Epidemiology and management. CNS Drugs. 2002;16:803–810
  42. Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem (Therapeutic implications). Clin Pharmacokinet. 1995;29:142–153
  43. Weitzel KW, Wickman JM, Augustin SG, et al. Zaleplon: A pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Clin Ther. 2000;22:1254–1267
  44. Zammit GK, Corser B, Doghramji K, et al. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med. 2006;2:417–423
  45. Blumer JL, Reed MD, Steinberg F, et al. Potential pharmacokinetic basis for zolpidem dosing in children with sleep difficulties. Clin Pharmacol Ther. 2008;83:551–558
  46. Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006;28:491–516
  47. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6:487–495
  48. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: Effect on sleep, quality of life, and work limitations. Sleep. 2007;30:959–968
  49. Guilleminault C, Pelayo R. Narcolepsy in children: A practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs. 2000;2:1–9
  50. Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci. 2002;25:283–313
  51. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology. 2001;57:2253–2258
  52. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59:1553–1562
  53. Littner M, Johnson SF, McCall WV, et al. Practice parameters for the treatment of narcolepsy: An update for 2000. Sleep. 2001;24:451–466
  54. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1705–1711
  55. Wise MS, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1712–1727
  56. Mitler MM, Hayduk R. Benefits and risks of pharmacotherapy for narcolepsy. Drug Saf. 2002;25:791–809
  57. Tafti M, Dauvilliers Y. Pharmacogenomics in the treatment of narcolepsy. Pharmacogenomics. 2003;4:23–33
  58. Amiri S, Mohammadi MR, Mohammadi M, et al. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:145–149
  59. Wigal SB, Biederman J, Swanson JM, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: Pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion J Clin Psychiatry. 2006;8:352–360
  60. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67:137–147
  61. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116:e777–e784
  62. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26:31–35
  63. Borgen LA, Cook HN, Hornfeldt CS, et al. Sodium oxybate (GHB) for treatment of cataplexy. Pharmacotherapy. 2002;22:798–799
  64. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25:42–49
  65. Robinson DM, Keating GM. Sodium oxybate: A review of ts use in the management of narcolepsy. CNS Drugs. 2007;21:337–354
  66. Fuller DE, Hornfeldt CS, Kelloway JS, et al. The Xyrem risk management program. Drug Saf. 2004;27:293–306
  67. Xyrem . Date-rape drug approved for cataplexy. Nursing. 2002;32:24
  68. Scharf MB, Lai AA, Branigan B, et al. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep. 1998;21:507–514
  69. Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology. 1993;113:76–82
  70. Nishino S, Fruhstorfer B, Arrigoni J, et al. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther. 1993;264:1079–1084
  71. Marcus CL, Carroll JL, Bamford O, et al. Supplemental oxygen during sleep in children with sleep-disordered breathing. Am J Respir Crit Care Med. 1995;152:1297–1301
  72. Marcus CL. Sleep-disordered breathing in children. Am J Respir Crit Care Med. 2001;164:16–30
  73. Marcus CL, Ward SL, Mallory GB, et al. Use of nasal continuous positive airway pressure as treatment of childhood obstructive sleep apnea. J Pediatr. 1995;127:88–94
  74. Hudgel DW, Thanakitcharu S. Pharmacologic treatment of sleep-disordered breathing. Am J Respir Crit Care Med. 1998;158:691–699
  75. Thornton WK, Roberts DH. Nonsurgical management of the obstructive sleep apnea patient. J Oral Maxillofac Surg. 1996;54:1103–1108
  76. Brouillette RT, Manoukian JJ, Ducharme FM, et al. Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea. J Pediatr. 2001;138:838–844
  77. Marcus CL. Nasal steroids as treatment for obstructive sleep apnea: Don't throw away the scalpel yet. J Pediatr. 2001;138:795–797
  78. Kheirandish L, Goldbart AD, Gozal D. Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children. Pediatrics. 2006;117:e61–e66
  79. Picchietti D, Allen RP, Walters AS, et al. Restless legs syndrome: Prevalence and impact in children and adolescents—The Peds REST study. Pediatrics. 2007;120:253–266
  80. Picchietti DL, Stevens HE: Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med 2007 [Epub ahead of print]
  81. Mohri I, Kato-Nishimura K, Tachibana N, et al: Restless legs syndrome (RLS): An unrecognized cause for bedtime problems and insomnia in children. Sleep Med 2007 [Epub ahead of print]
  82. Picchietti DL, Underwood DJ, Farris WA, et al. Further studies on periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder. Mov Disord. 1999;14:1000–1007
  83. Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder (An American Academy of Sleep Medicine Review). Sleep. 1999;22:970–999
  84. Picchietti D. Is iron deficiency an underlying cause of pediatric restless legs syndrome and of attention-deficit/hyperactivity disorder?. Sleep Med. 2007;8:693–694
  85. Patrick LR. Restless legs syndrome: Pathophysiology and the role of iron and folate. Altern Med Rev. 2007;12:101–112
  86. Konofal E, Cortese S, Marchand M, et al. Impact of restless legs syndrome and iron deficiency on attention-deficit/hyperactivity disorder in children. Sleep Med. 2007;8:711–715
  87. Dosman CF, Brian JA, Drmic IE, et al. Children with autism: Effect of iron supplementation on sleep and ferritin. Pediatr Neurol. 2007;36:152–158
  88. Beard JL. Iron status and periodic limb movements of sleep in children: A causal relationship?. Sleep Med. 2004;5:89–90
  89. Simakajornboon N, Gozal D, Vlasic V, et al. Periodic limb movements in sleep and iron status in children. Sleep. 2003;26:735–738
  90. Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001;56:263–265
  91. Littner MR, Kushida C, Anderson WM, et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004;27:557–559
  92. Chesson AL, Wise M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder (An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine). Sleep. 1999;22:961–968
  93. Walters AS, Mandelbaum DE, Lewin DS, et al. Dopaminergic Therapy Study Group Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Pediatr Neurol. 2000;22:182–186
  94. Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep. 1996;19:801–810
  95. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205–213
  96. Burg FIJ, Polin R, Gershon A. Gellis and Kagan‘s Current Pediatric Therapy. (ed 17). Philadelphia, PA: Saunders Company; 2002;
  97. Walters AS, Hening W. Clinical presentation and neuropharmacology of restless legs syndrome. Clin Neuropharmacol. 1987;10:225–237
  98. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology. 1993;43:445
  99. Allen RP, Earley CJ. Restless legs syndrome: A review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18:128–147
  100. Earley CJ, Hyland K, Allen RP. CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. Mov Disord. 2001;16:144–149
  101. Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54:1698–1700
  102. Allen RP, Mignot E, Ripley B, et al. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology. 2002;59:639–641
  103. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord. 2007;22:213–219
  104. Allen RP, Ritchie SY. Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. Sleep Med 2007 [Eput ahead of print]
  105. Quilici S, Abrams KR, Nicolas A, et al: Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008 [Epub ahead of print]
  106. Montplaisir J, Nicolas A, Denesle R, et al. Restless legs syndrome improved by pramipexole: A double-blind randomized trial. Neurology. 1999;52:938–943

PII: S1071-9091(08)00028-4

doi: 10.1016/j.spen.2008.03.004

Seminars in Pediatric Neurology
Volume 15, Issue 2 , Pages 79-90 , June 2008

Article Tools